Waldenström J. Studein uber porphyrie. Acta Med Scand. 1937. 82:1.
Zelickson AS. Phototoxic reaction with nalidixic acid. JAMA. 1964 Nov 9. 190:556-7. [QxMD MEDLINE Link].
Burry JN, Lawrence JR. Phototoxic blisters from high frusemide dosage. Br J Dermatol. 1976 May. 94(5):495-9. [QxMD MEDLINE Link].
Stenberg A. Pseudoporphyria and sunbeds. Acta Derm Venereol. 1990. 70(4):354-6. [QxMD MEDLINE Link].
Wilson CL, Mendelsohn SS. Pseudoporphyria and sunbeds, a coincidence in identical twins?. Br J Dermatol. 1991 Aug. 125(2):191. [QxMD MEDLINE Link].
Quaiser S, Khan R, Khan AS. Drug induced pseudoporphyria in CKD: A case report. Indian J Nephrol. 2015 Sep-Oct. 25 (5):307-9. [QxMD MEDLINE Link].
Keane JT, Pearson RW, Malkinson FD. Nalidixic acid-induced photosensitivity in mice: a model for pseudoporphyria. J Invest Dermatol. 1984 Mar. 82(3):210-3. [QxMD MEDLINE Link].
Dabski C, Beutner EH. Studies of laminin and type IV collagen in blisters of porphyria cutanea tarda and drug-induced pseudoporphyria. J Am Acad Dermatol. 1991 Jul. 25(1 Pt 1):28-32. [QxMD MEDLINE Link].
Markova A, Lester J, Wang J, Robinson-Bostom L. Diagnosis of common dermopathies in dialysis patients: a review and update. Semin Dial. 2012 Jul. 25(4):408-18. [QxMD MEDLINE Link].
Onelmis H, Sener S, Sasmaz S, Ozer A. Cutaneous changes in patients with chronic renal failure on hemodialysis. Cutan Ocul Toxicol. 2012 Dec. 31(4):286-91. [QxMD MEDLINE Link].
Pranteda G, Bottoni U, Tayefeh Jafari M, Pranteda G, De Micco S, Muscianese M, et al. Dialysis-associated pseudoporphyria successfully treated with vitamin D. Report of two cases. G Ital Dermatol Venereol. 2015 Jun. 150 (3):327-9. [QxMD MEDLINE Link].
Habif TP, ed. Light-related diseases and disorders of pigmentation. Clinical Dermatology. 6th ed. Elsevier; 2016. Chapter 19.
Suarez SM, Cohen PR, DeLeo VA. Bullous photosensitivity to naproxen: "pseudoporphyria". Arthritis Rheum. 1990 Jun. 33(6):903-8. [QxMD MEDLINE Link].
Beer K, Applebaum D, Nousari C. PseudoPorphyria: discussion of etiologic agents. J Drugs Dermatol. 2014 Aug. 13 (8):990-2. [QxMD MEDLINE Link].
Al-Khenaizan S, Schechter JF, Sasseville D. Pseudoporphyria induced by propionic acid derivatives. J Cutan Med Surg. 1999 Jan. 3(3):162-6. [QxMD MEDLINE Link].
Taylor BJ, Duffill MB. Pseudoporphyria from nonsteroidal antiinflammatory drugs. N Z Med J. 1987 May 27. 100(824):322-3. [QxMD MEDLINE Link].
Allen R, Rogers M, Humphrey I. Naproxen induced pseudoporphyria in juvenile chronic arthritis. J Rheumatol. 1991 Jun. 18(6):893-6. [QxMD MEDLINE Link].
Girschick HJ, Hamm H, Ganser G, Huppertz HI. Naproxen-induced pseudoporphyria: appearance of new skin lesions after discontinuation of treatment. Scand J Rheumatol. 1995. 24(2):108-11. [QxMD MEDLINE Link].
Howard AM, Dowling J, Varigos G. Pseudoporphyria due to naproxen. Lancet. 1985 Apr 6. 1(8432):819-20. [QxMD MEDLINE Link].
Judd LE, Henderson DW, Hill DC. Naproxen-induced pseudoporphyria. A clinical and ultrastructural study. Arch Dermatol. 1986 Apr. 122(4):451-4. [QxMD MEDLINE Link].
Levy ML, Barron KS, Eichenfield A, Honig PJ. Naproxen-induced pseudoporphyria: a distinctive photodermatitis. J Pediatr. 1990 Oct. 117(4):660-4. [QxMD MEDLINE Link].
Sterling JC, Pye RJ. Naproxen-induced pseudoporphyria. Br J Rheumatol. 1987 Jun. 26(3):210-1. [QxMD MEDLINE Link].
Krischer J, Scolari F, Kondo-Oestreicher M, Vollenweider-Roten S, Saurat JH, Pechere M. Pseudoporphyria induced by nabumetone. J Am Acad Dermatol. 1999 Mar. 40(3):492-3. [QxMD MEDLINE Link].
Magro CM, Crowson AN. Pseudoporphyria associated with Relafen therapy. J Cutan Pathol. 1999 Jan. 26(1):42-7. [QxMD MEDLINE Link].
Ingrish G, Rietschel RL. Oxaprozin-induced pseudoporphyria. Arch Dermatol. 1996 Dec. 132(12):1519-20. [QxMD MEDLINE Link].
O'Hagan AH, Irvine AD, Allen GE, Walsh M. Pseudoporphyria induced by mefenamic acid. Br J Dermatol. 1998 Dec. 139(6):1131-2. [QxMD MEDLINE Link].
Markus R, Reddick ME, Rubenstein MC. Rofecoxib-induced pseudoporphyria. J Am Acad Dermatol. 2004 Apr. 50(4):647-8. [QxMD MEDLINE Link].
Bilsland D, Douglas WS. Sunbed pseudoporphyria induced by nalidixic acid. Br J Dermatol. 1990 Oct. 123(4):547. [QxMD MEDLINE Link].
Birkett DA, Garretts M, Stevenson CJ. Phototoxic bullous eruptions due to nalidixic acid. Br J Dermatol. 1969 May. 81(5):342-4. [QxMD MEDLINE Link].
Epstein JH, Seibert JS. Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization. Arch Dermatol. 1976 May. 112(5):661-6. [QxMD MEDLINE Link].
Hawk JL. Skin changes resembling hepatic cutaneous porphyria induced by oxytetracycline photosensitization. Clin Exp Dermatol. 1980 Sep. 5(3):321-5. [QxMD MEDLINE Link].
Phung TL, Pipkin CA, Tahan SR, Chiu DS. Beta-lactam antibiotic-induced pseudoporphyria. J Am Acad Dermatol. 2004 Aug. 51(2 Suppl):S80-2. [QxMD MEDLINE Link].
Degiovanni CV, Darley CR. Pseudoporphyria occurring during a course of ciprofloxacin. Clin Exp Dermatol. 2008 Jan. 33(1):109-10. [QxMD MEDLINE Link].
Dolan CK, Hall MA, Blazes DL, Norwood CW. Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol. 2004 Oct. 43(10):768-71. [QxMD MEDLINE Link].
Kwong WT, Hsu S. Pseudoporphyria associated with voriconazole. J Drugs Dermatol. 2007 Oct. 6(10):1042-4. [QxMD MEDLINE Link].
Breier F, Feldmann R, Pelzl M, Gschnait F. Pseudoporphyria cutanea tarda induced by furosemide in a patient undergoing peritoneal dialysis. Dermatology. 1998. 197(3):271-3. [QxMD MEDLINE Link].
Baker EJ, Reed KD, Dixon SL. Chlorthalidone-induced pseudoporphyria: clinical and microscopic findings of a case. J Am Acad Dermatol. 1989 Nov. 21(5 Pt 1):1026-9. [QxMD MEDLINE Link].
Perez-Bustillo A, Sanchez-Sambucety P, Suarez-Amor O, Rodriiguez-Prieto MA. Torsemide-induced pseudoporphyria. Arch Dermatol. 2008 Jun. 144(6):812-3. [QxMD MEDLINE Link].
Leitao EA, Person JR. Bumetanide-induced pseudoporphyria. J Am Acad Dermatol. 1990 Jul. 23(1):129-30. [QxMD MEDLINE Link].
Parodi A, Guarrera M, Rebora A. Amiodarone-induced pseudoporphyria. Photodermatol. 1988 Jun. 5(3):146-7. [QxMD MEDLINE Link].
Laidman PJ, Gebauer K, Trotter J. 5-Fluorouracil-induced pseudoporphyria. Aust N Z J Med. 1992 Aug. 22(4):385. [QxMD MEDLINE Link].
Timmer-de Mik L, Kardaun SH, Kramer MH, Hayes DP, Bousema MT. Imatinib-induced pseudoporphyria. Clin Exp Dermatol. 2008 Dec 9. [QxMD MEDLINE Link].
Sanz-Motilva V, Martorell-Calatayud A, Llombart B, Requena C, Serra-Guillén C, Nagore E, et al. Sunitinib-induced pseudoporphyria. J Eur Acad Dermatol Venereol. 2015 Sep. 29 (9):1848-50. [QxMD MEDLINE Link].
Sola R, Puig LL, Ballarin JA, Donate T, del Rio G. Pseudoporphyria cutanea tarda associated with cyclosporine therapy. Transplantation. 1987 May. 43(5):772. [QxMD MEDLINE Link].
Hivnor C, Nosauri C, James W, Poh-Fitzpatrick M. Cyclosporine-induced pseudoporphyria. Arch Dermatol. 2003 Oct. 139 (10):1373-4. [QxMD MEDLINE Link].
Baer RL. Cutaneous skin changes probably due to pyridoxine abuse. J Am Acad Dermatol. 1984 Mar. 10(3):527-8. [QxMD MEDLINE Link].
McDonagh AJ, Harrington CI. Pseudoporphyria complicating etretinate therapy. Clin Exp Dermatol. 1989 Nov. 14(6):437-8. [QxMD MEDLINE Link].
Riordan CA, Anstey A, Wojnarowska F. Isotretinoin-associated pseudoporphyria. Clin Exp Dermatol. 1993 Jan. 18(1):69-71. [QxMD MEDLINE Link].
Hazen PG. Pseudoporphyria in a patient receiving carisoprodol/aspirin therapy. J Am Acad Dermatol. 1994 Sep. 31(3 Pt 1):500. [QxMD MEDLINE Link].
Borroni G, Brazzelli V, Baldini F, et al. Flutamide-induced pseudoporphyria. Br J Dermatol. 1998 Apr. 138(4):711-2. [QxMD MEDLINE Link].
Santo Domingo D, Stevenson ML, Auerbach J, Lerman J. Finasteride-induced pseudoporphyria. Arch Dermatol. 2011 Jun. 147 (6):747-8. [QxMD MEDLINE Link].
Gilchrest B, Rowe JW, Mihm MC Jr. Bullous dermatosis of hemodialysis. Ann Intern Med. 1975 Oct. 83(4):480-3. [QxMD MEDLINE Link].
Bergler-Czop B, Brzezińska-Wcisło L. Pseudoporphyria induced by hemodialysis. Postepy Dermatol Alergol. 2014 Feb. 31 (1):53-5. [QxMD MEDLINE Link].
Judd L. Pseudoporphyria due to cola. Int J Dermatol. 1991 Sep. 30(9):674-5. [QxMD MEDLINE Link].
Silver EA, Silver AH, Silver DS, McCalmont TH. Pseudoporphyria induced by oral contraceptive pills. Arch Dermatol. 2003 Feb. 139(2):227-8. [QxMD MEDLINE Link].
Oh C, Jones B, Solomon R, Egan CA. Pseudoporphyria secondary to narrowband UVB phototherapy for psoriasis. Australas J Dermatol. 2006 May. 47(2):134-6. [QxMD MEDLINE Link].
Lenfestey A, Friedmann D, Burke WA. Metformin-induced pseudoporphyria. J Drugs Dermatol. 2012 Nov. 11 (11):1272. [QxMD MEDLINE Link].
Turnbull N, Callan M, Staughton RC. Diclofenac-induced pseudoporphyria; an under-recognized condition?. Clin Exp Dermatol. 2014 Apr. 39 (3):348-50. [QxMD MEDLINE Link].
Garg T, Barara M, Chander R, Meena S, Agarwal S. Pseudoporphyria: A Case Report. Indian J Dermatol. 2015 May-Jun. 60 (3):324. [QxMD MEDLINE Link].
Handler NS, Handler MZ, Stephany MP, Handler GA, Schwartz RA. Porphyria cutanea tarda: an intriguing genetic disease and marker. Int J Dermatol. 2017 Jun. 56 (6):e106-e117. [QxMD MEDLINE Link].
Zhao CY, Frew JW, Muhaidat J, Cheung K, Lee P, Poulos V, et al. Chlorophyll-induced pseudoporphyria with ongoing photosensitivity after cessation - a case series of four patients. J Eur Acad Dermatol Venereol. 2016 Jul. 30 (7):1239-42. [QxMD MEDLINE Link].
Rossi E, Borchard K, Cole JM. Pseudoporphyria following self-medication with chlorophyll. Australas J Dermatol. 2015 Feb. 56 (1):47-8. [QxMD MEDLINE Link].
Burns DA. Naproxen pseudoporphyria in a patient with vitiligo. Clin Exp Dermatol. 1987 Jul. 12(4):296-7. [QxMD MEDLINE Link].
Motley RJ. Pseudoporphyria due to dyazide in a patient with vitiligo. BMJ. 1990 Jun 2. 300(6737):1468. [QxMD MEDLINE Link].
Wallace CA, Farrow D, Sherry DD. Increased risk of facial scars in children taking nonsteroidal antiinflammatory drugs. J Pediatr. 1994 Nov. 125(5 Pt 1):819-22. [QxMD MEDLINE Link].
Schanbacher CF, Vanness ER, Daoud MS, Tefferi A, Su WP. Pseudoporphyria: a clinical and biochemical study of 20 patients. Mayo Clin Proc. 2001 May. 76 (5):488-92. [QxMD MEDLINE Link].
Brinster NK, Liu V, Diwan AH, McKee PH, eds. Pseudoporphyria. Dermatopathology: High-Yield Pathology. Elsevier; 2011.
Mehta S, Lang B. Long-term followup of naproxen-induced pseudoporphyria in juvenile rheumatoid arthritis. Arthritis Rheum. 1999 Oct. 42 (10):2252-4. [QxMD MEDLINE Link].
Poblete-Gutiérrez FJ, Weitz JI. Porphyria. Bolognia JL, Jorizzo JL, Schaffer JV, et al, eds. Dermatology. 3rd ed. Elsevier; 2012. Chapter 49.
Sabanis N, Paschou E, Gavriilaki E, Kalaitzoglou A, Papanikolaou D, Vasileiou S, et al. Acquired reactive perforating collagenosis and pseudoporphyric bullous dermatosis in a hemodialysis patient. Hemodial Int. 2016 Jul. 20 (3):E14-E18. [QxMD MEDLINE Link].
Lang BA, Finlayson LA. Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr. 1994 Apr. 124(4):639-42. [QxMD MEDLINE Link].
Papadopoulos AJ, Schwartz RA, Fekete Z, Kihiczak G, Samady JA, Atkin SH, et al. Pseudoporphyria: an atypical variant resembling toxic epidermal necrolysis. J Cutan Med Surg. 2001 Nov-Dec. 5 (6):479-85. [QxMD MEDLINE Link].
Fevang SA, Kroon S, Skadberg Ø. Pseudoporphyria or porphyria cutanea tarda? Diagnostic and treatment difficulties. Acta Derm Venereol. 2008. 88 (4):426-7. [QxMD MEDLINE Link].
Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol. 1992 Feb. 19(1):40-7. [QxMD MEDLINE Link].
Pérez NO, Esturo SV, Viladomiu Edel A, Moreno AJ, Valls AT. Pseudoporphyria induced by imatinib mesylate. Int J Dermatol. 2014 Feb. 53 (2):e143-4. [QxMD MEDLINE Link].
Mahon C, Purvis D, Laughton S, Bradbeer P, Teague L. Imatinib mesylate-induced pseudoporphyria in two children. Pediatr Dermatol. 2014 Sep-Oct. 31 (5):603-7. [QxMD MEDLINE Link].
Martinez-Mera C, Capusan TM, Herrero-Moyano M, Urquía Renke A, Steegmann Olmedillas JL, de Argila D. Imatinib-induced pseudoporphyria. Clin Exp Dermatol. 2018 Jun. 43 (4):463-466. [QxMD MEDLINE Link].
Batrani M, Salhotra M, Kubba A, Agrawal M. Imatinib mesylate-induced pseudoporphyria in a patient with chronic myeloid leukemia. Indian J Dermatol Venereol Leprol. 2016 Nov-Dec. 82 (6):727-729. [QxMD MEDLINE Link].
Guiotoku MM, Pereira Fde P, Miot HA, Marques ME. Pseudoporphyria induced by dialysis treated with oral N-acetylcysteine. An Bras Dermatol. 2011 Mar-Apr. 86 (2):383-5. [QxMD MEDLINE Link].
Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. Br J Dermatol. 2000 Mar. 142 (3):580-1. [QxMD MEDLINE Link].
Katoulis AC, Ferra D, Toumbis E, Papadavid E, Kanelleas A, Panayiotides I, et al. Pseudoporphyria associated with nonhemodialyzed renal insufficiency, successfully treated with oral N-acetylcysteine. Case Rep Dermatol Med. 2013. 2013:271873. [QxMD MEDLINE Link].
Velioglu A, Ergun T, Ozener C. Pseudoporphyria in a peritoneal dialysis patient. Perit Dial Int. 2015 Mar-Apr. 35 (2):234-5. [QxMD MEDLINE Link].
El Kabbaj D, Laalou A, Alouane Z, Bahadi A, Oualim Z. Hemodialysis-associated pseudoporphyria resistant to N-acetylcysteine. Saudi J Kidney Dis Transpl. 2011 Mar. 22 (2):311-4. [QxMD MEDLINE Link].
Azak A, Yenigün E, Koçak G, Huddam B, Kahve B. Pseudoporphyria in a hemodialysis patient successfully treated with oral glutamine. Hemodial Int. 2013 Jul. 17 (3):466-7. [QxMD MEDLINE Link].
James WD, Berger TG, Elston DM, eds. Errors in Metabolism. Andrews’ Diseases of the Skin. 12th ed. Elsevier; 2016. Chapter 26.